Journal of the American Society of Nephrology
2009 JASN IMPACT FACTOR 7.689 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on June 25, 2009
Journal of the American Society of Nephrology
© 2009 American Society of Nephrology
doi: 10.1681/ASN.2009040444
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2009040444v1
20/7/1436    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, A. K.
Right arrow Articles by Szczech, L. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Singh, A. K.
Right arrow Articles by Szczech, L. A.


UP FRONT MATTERS: JASN Debates

Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia

Ajay K. Singh 1, Jonathan Himmelfarb *1, and Lynda Anne Szczech {dagger}1

Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts


*Kidney Research Center, University of Washington, Seattle, Washington; {dagger}Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, North Carolina


1 To whom correspondence should be addressed. E-mail: asingh{at}partners.org.


   Abstract

Some time has passed since the torrent of discussion surrounding the cardiovascular risk of pushing up hemoglobin concentrations in dialysis patients with erythropoietin. The debate here reflects a look back on the tension produced by confusing data and outcomes. Is it the target hemoglobin per se or the high doses of erythropoietin in subsets of resistant patients that is the problem? You decide.




This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
A. K. Singh
ESAs in Dialysis Patients: Are You a Hedgehog or a Fox?
J. Am. Soc. Nephrol., April 1, 2010; 21(4): 543 - 546.
[Full Text] [PDF]


Home page
CJASNHome page
A. K. Singh
The FDA's Perspective on the Risk for Rapid Rise in Hemoglobin in Treating CKD Anemia: Quo Vadis
Clin. J. Am. Soc. Nephrol., April 1, 2010; 5(4): 553 - 556.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. K. Singh
Does TREAT Give the Boot to ESAs in the Treatment of CKD Anemia?
J. Am. Soc. Nephrol., January 1, 2010; 21(1): 2 - 6.
[Full Text] [PDF]


Home page
NEJMHome page
H. F. Bunn
End Run around Epo
N. Engl. J. Med., November 5, 2009; 361(19): 1901 - 1903.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP